Aytu biopharma reports fiscal 2025 full year and fourth quarter operational and financial results and outlines commercial launch plans for exxua(tm)

Full year fiscal 2025 net revenue of $66.4 million full year fiscal 2025 net loss of $13.6 million full year fiscal 2025 adjusted ebitda1 of $9.2 million $31.0 million cash balance at june 30, 2025 exclusive agreement in june 2025 to commercialize exxua™ (gepirone) extended-release tablets ("exxua") is expected to serve as a major growth catalyst; the company anticipates launching exxua in the fourth calendar quarter of 2025 as a centerpiece of its commercial efforts as it enters the over $22 billion united states prescription major depressive disorder ("mdd") market with what the company believes to be a novel first-in-class oral selective serotonin 5ht1a receptor agonist for adults with mdd company to host conference call and webcast today, september 23, 2025, at 4:30 p.m. eastern time denver, co / access newswire / september 23, 2025 / aytu biopharma, inc. (the "company" or "aytu") (nasdaq:aytu), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced operational and financial results for the fiscal 2025 full year and fourth quarter.
AYTU Ratings Summary
AYTU Quant Ranking